Tislelizumab

Tislelizumab is a humanized monoclonal antibody sold under the brand name Tevimbra that targets the programmed death receptor 1, or PD-1, on immune cells. By blocking PD-1 it stops tumors from using that receptor to suppress the immune system, allowing T cells to attack cancer more effectively, the same checkpoint inhibitor strategy used by other PD-1 antibodies. It was first approved in China in December 2019, then in the European Union in September 2023 and in the United States in March 2024, with Australia following in May 2024. Tislelizumab is given only by intravenous injection and is approved for several solid tumors, including esophageal squamous cell carcinoma after prior chemotherapy, gastric and gastroesophageal junction adenocarcinoma, Hodgkin lymphoma after multiple earlier treatments, and urothelial carcinoma with high PD-L1 expression.